Objective: The purpose of this study was to compare impalpable breast carcinomas revealed by core biopsy with those revealed by surgical biopsy with respect to the frequency of performing a single surgical procedure and finding tumor at the margins of the lumpectomy specimen.
Materials And Methods: Retrospective review found 197 solitary impalpable breast carcinomas revealed by core biopsy using a 14-gauge needle (n = 90) or surgical biopsy after needle localization (n = 107). Lumpectomy was the surgical treatment in 62 (69%) of the 90 cancers revealed by core biopsy and in 74 (69%) of the 107 cancers revealed by surgical biopsy. Records were reviewed to determine the number and type of surgeries performed on each patient and the histopathologic findings at surgery. Lumpectomy margins were considered positive if tumor was present at the inked margins of a lumpectomy performed as a separate procedure after the diagnostic biopsy.
Results: A single surgical procedure was performed 76 (84%) of the 90 patients who underwent core biopsy versus 31 (29%) of the 107 patients who underwent surgical biopsy. This difference was statistically significant (p < .00001). Tumor was present at the lumpectomy margins in five (8%) of the 62 cancers revealed by core biopsy versus four (5%) of the 74 cancers diagnosed by surgical biopsy. This difference was not statistically significant (p = .7).
Conclusion: A single surgical procedure was performed significantly more often in patients in whom impalpable breast cancer was revealed by core biopsy. The likelihood of obtaining tumor-free margins at lumpectomy did not differ significantly for cancers revealed by either method. These data indicate that core biopsy provides the information necessary to plan surgical treatment and could decrease the number of surgical procedures required in patients with impalpable breast cancer.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2214/ajr.168.2.9016234 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Assessing Malignant Risk in B3 Breast Lesions: Clinical Insights and Implications.
J Clin Med
December 2024
Multidisciplinary Breast Centre, Dipartimento Scienze della Salute della Donna e del Bambino e di Sanità Pubblica, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy.
: B3 breast lesions, characterized by uncertain malignant potential, pose a significant challenge for clinicians. With the increasing use of preoperative biopsies, there is a need for careful management strategies, including watchful waiting, vacuum-assisted excision (VAE), and surgery. This study aims to assess the concordance between preoperative biopsy findings and postoperative histology, with a focus on evaluating the positive predictive value (PPV) for malignancy in B3 lesions.
View Article and Find Full Text PDFDWI in the Differentiation of Malignant and Benign Breast Lesions Presenting with Non-Mass Enhancement on CE-MRI.
Cancers (Basel)
December 2024
Department of Diagnostic and Interventional Radiology, University Hospital Split, Spinčićeva 1, 21000 Split, Croatia.
Article Synopsis
- The study examined if ADC map values of breast lesions with non-mass enhancement on MRI could distinguish between benign and malignant cases.
- A total of 136 patients underwent ultrasound-guided biopsies, and radiologists measured ADC values independently, comparing results to pathology reports.
- The whole tumor region of interest (ROI) showed the highest sensitivity at 91% for detecting benign lesions, while there were no significant ADC value differences between fatty and dense breast tissues.
Clinical feasibility of MRI-guided in-bore prostate biopsies at 0.55T.
Abdom Radiol (NY)
January 2025
University of Michigan, Ann Arbor, USA.
Objective: In-bore MRI-guided biopsy allows direct visualization of suspicious lesions, biopsy needles, and trajectories, allowing accurate sampling when MRI-ultrasound fusion biopsy is not feasible. However, its use has been limited. Wide-bore, lower-field, and lower-cost scanners could help address these issues, but their feasibility for prostate biopsy is unknown.
View Article and Find Full Text PDF[The significance and advancements of circulating tumor DNA in the diagnosis and treatment of operable non-small cell lung cancer].
Zhonghua Wai Ke Za Zhi
January 2025
Department of Thoracic Surgery, Peking University People's Hospital, Beijing100044, China.
Non-small cell lung cancer, characterized by high incidence and mortality rates, significantly threatens human health. Precisely assessing patient prognosis and implementing adaptive treatment strategies have emerged as pivotal issues in contemporary thoracic oncology. Postoperative minimal residual disease (MRD) detection through liquid biopsy has demonstrated substantial potential.
View Article and Find Full Text PDFTailoring Renal Mass Biopsy: Optimal Core Number and Location Based on Tumor Size for Enhanced Diagnostic Accuracy- A Prospective Ex-Vivo Study.
Urology
January 2025
Urology Department, Shohada-e-Tajrish Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Electronic address:
Objective: To determine the optimal number and location of biopsy cores in renal masses based on mass size in order to maximize diagnostic accuracy.
Methods: This observational study included 360 patients with renal masses, who were divided equally into six groups. Each group was matched in terms of mass size (mass size category: ≤ 4 cm (T1a), 4-7 cm (T1b), 7-10 cm (T2a), and > 10 cm (T2b)).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!